Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

Kyoto University

Status and phase: Completed; Phase 4

Conditions: Hepatitis C, Chronic

Treatments: Drug: interferon-alfa-2b and ribavirin

Study type: Interventional

Funder types: Other

Identifiers

NCT00375661

O2006-415

Details and patient eligibility

About

The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.

Enrollment: 100 patients

Sex: All

Ages: 25 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of Hepatocellular carcinoma due to Chronic Hepatitis C Virus Infection.
• Must be treated with curative treatment for primary tumor using either surgical resection or radiofrequency ablation therapy

Exclusion criteria

• No recurrence of hepatocellular carcinoma 3 months after the primary treatment
• Renal dysfunction

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

interferon

No Intervention group

Treatment:

Drug: interferon-alfa-2b and ribavirin